The information contained in this website is of a general nature, is for informational purposes only and does not constitute professional advice
Vasculitis (NHS Choices), Vasculitis (patient.info), Types of vasculitis by size of arteries affected (Vasculitis UK), Vasculitis (PCDS)
Behcet's disease (NHS Choices)
Buerger's disease (Vasculitis UK)
Churg Strauss syndrome (Vasculitis UK)
Giant cell arteritis (NHS Choices) / Giant cell arteritis (CKS)
Wegener's granulomatosis (NHS Choices)
Henoch-Schonlein purpura (HSP) (NHS Choices)
A 2-year-old boy is brought to your morning surgery by his father who gives a history of a fever for 7 days associated with a rash. Clinical assessment suggests a possible diagnosis of Kawasaki’s disease. Which ONE of the following symptoms or signs supports the diagnosis of Kawasaki’s disease?
Changes in limb proximities
Unilateral conjunctivitis
Changes in the lips and oral cavity
Inguinal lymphadenopathy
Absence of a rash
An idiopathic self-limiting systemic vasculitis that most often affects children aged 6 months to 5 years. It is the leading cause of acquired heart disease in children in the developed world. In order to reach a diagnosis of Kawasaki disease, there must be a history of fever of at least 5 days' duration and at least 4 of the following 5 clinical features:
Inflammation and irritation of the lips, mouth and/or tongue (eg, cracked lips, strawberry tongue, inflamed mucosa of mouth or pharynx)
Erythema, oedema and/or desquamation of the extremities
Bilateral dry conjunctivitis
Widespread non-vesicular rash
Cervical lymphadenopathy > 1.5 cm in size
References
Kawasaki disease (NHS Choices), Kawasaki disease (BMJ, 2014)
Microscopic polyangiitis (Oxford University Hospitals)
Medium sized artery vasculitis. M>F. Relatively rare. Polyarthralgia is present in 60% of cases and myalgia in 30–80%. Definitive diagnosis is dependent on histological or angiographic demonstraton of microaneurysms in hepatic, renal or intestinal vessels
Polyarteritis nodosa (GOSH)
Polymyalgia Rheumatica (PMR) (NHS Choices), PMR (CKS)
Takayasu arteritis (Vasculitis UK)
Atorvastatin 20 mg is recommended for primary prevention of CVD for people with a 10% or greater CVD risk over 10 years. Atorvastatin 80 mg is first-line for secondary prevention, although a lower dose or an alternative drug may be required if there is a high risk of adverse effects or significant drug interactions.
Low dose aspirin is of definite and substantial value for people who already have occlusive vascular disease – risk calculations are irrelevant to this group.
However, in primary prevention, without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.